Tandem Investment Partners LLC Purchases 273 Shares of Thermo Fisher Scientific Inc. $TMO

Tandem Investment Partners LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,821 shares of the medical research company’s stock after purchasing an additional 273 shares during the quarter. Tandem Investment Partners LLC’s holdings in Thermo Fisher Scientific were worth $738,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Talbot Financial LLC raised its position in shares of Thermo Fisher Scientific by 40.8% in the second quarter. Talbot Financial LLC now owns 24,499 shares of the medical research company’s stock valued at $9,933,000 after purchasing an additional 7,097 shares during the period. Willner & Heller LLC increased its position in Thermo Fisher Scientific by 170.4% during the second quarter. Willner & Heller LLC now owns 1,152 shares of the medical research company’s stock worth $467,000 after acquiring an additional 726 shares during the period. Wells Trecaso Financial Group LLC increased its position in Thermo Fisher Scientific by 2.7% during the second quarter. Wells Trecaso Financial Group LLC now owns 11,228 shares of the medical research company’s stock worth $4,553,000 after acquiring an additional 290 shares during the period. Sava Infond d.o.o. increased its position in Thermo Fisher Scientific by 48.3% during the second quarter. Sava Infond d.o.o. now owns 4,390 shares of the medical research company’s stock worth $1,780,000 after acquiring an additional 1,430 shares during the period. Finally, LGT Fund Management Co Ltd. increased its position in Thermo Fisher Scientific by 8.5% during the second quarter. LGT Fund Management Co Ltd. now owns 7,642 shares of the medical research company’s stock worth $3,099,000 after acquiring an additional 596 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 3.6%

TMO opened at $543.88 on Friday. The firm’s 50-day simple moving average is $482.58 and its 200-day simple moving average is $447.27. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The firm has a market cap of $205.37 billion, a price-to-earnings ratio of 31.46, a PEG ratio of 2.95 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 EPS. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 9.95%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TMO shares. Barclays boosted their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research report on Thursday. HSBC reaffirmed a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Finally, William Blair assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating on the stock. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $585.37.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.